Grifols, S.A. (LON: 0RDU)

Market Cap	4.70B
Revenue (ttm)	5.83B
Net Income (ttm)	134.38M
Shares Out	n/a
EPS (ttm)	0.20
PE Ratio	34.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,726
Average Volume	112,722
Open	8.83
Previous Close	8.84
Day's Range	8.69 - 9.18
52-Week Range	5.27 - 13.18
Beta	0.69
RSI	38.93
Earnings Date	Feb 28, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,744
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RDU

Financial Performance

In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.

Financial numbers in EUR